ong-term phase III study in patients with chronic pain.
Phase 3
- Conditions
- Chronic pain
- Registration Number
- JPRN-jRCT2080221311
- Lead Sponsor
- Hisamitsu Pharmaceutical Co., Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients with chronic pain persisting for at least 12 weeks before obtaining informed consent
Exclusion Criteria
- Patients with abnormalities at the site of application
- Patients in whom the primary cause of chronic pain (the target of evaluation) is considered to be persistent somatoform pain disorder
- Patients who are scheduled to undergo an operation with a potential influence on the evaluation of pain for at least 7 days before starting administration of the investigational drug
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method